Abstract
TER286 [γ-glutamyl-α-amino-β(2-ethyl-N,N,N′,N′-tetrakis(2-chloroethyl)phosphorodiamidate)-sulfonyl-propionyl-(R)-(−) phenylglycine] is a novel nitrogen mustard prodrug that is preferentially activated by glutathione S-transferase P1-1 (GSTP1-1). A human promyelocytic leukemia /TER286-resistant cell line was selected by chronic, long-term exposure to the prodrug. Although resistance was not readily achieved, eventually a 5-fold resistant clone was isolated. Cross-resistance to melphalan occurred, but not to doxorubicin (Adriamycin), taxol, and γ-glutamyl-S-(benzyl)cysteinyl-R(−)-phenyl glycine diethyl ester, a GSTP1-1 inhibitor. The protein and transcript levels and enzymatic activity of GSTP1-1 were reduced significantly in the selected resistant line. GSTα levels were unchanged, and GSTμ was undetectable. Although glutathione levels were elevated in human promyelocytic leukemia/TER286 cells, no changes in the expression of thiol-related genes including γ-glutamylcysteine synthetase, γ-glutamyl transpeptidase, or multidrug resistance protein were found. A 7-fold increase in catalase expression in the resistant cell line indicated an adaptive response to oxidative and electrophilic stress, and this was also reflected in the lower prevalence of drug-induced DNA single-strand breaks in the resistant cells. Mouse embryo fibroblast GSTP1-1−/− cells exhibited 2-fold resistance to TER286 compared with GSTP1-1+/+ cells. NIH3T3 cells transfected with combinations of γ-GCS and multidrug resistance protein exhibited enhanced resistance to TER286, although the degree of resistance was impaired by cotransfection of GSTP1-1. These results are consistent with responses in the TER286-resistant cells indicative of GSTP1-1-mediated mechanism of activation. In consequence, these data support the rationale that tumors expressing high levels of GSTP1-1 will be more sensitive to the cytotoxic effects of the drug.
Footnotes
- Received November 8, 1999.
- Accepted March 27, 2000.
-
Kenneth D. Tew, Department of Pharmacology, Fox Chase Cancer Center, 7701 Burholme Ave., Philadelphia, PA 19111. E-mail:kd_tew{at}fccc.edu
-
This work was supported in part by National Institutes of Health Grants CA06927 and RR05539, NIH Grant CA53893 (to K.D.T.), and appropriation from the Commonwealth of Pennsylvania.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|